Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in Germany align with existing clinical trial data.

This study suggests that the combination of bendamustine and rituximab is at least as effective and possibly offers a better therapeutic index than other standard regimens as first-line treatment for certain lymphoma patients.

This review highlights that dermatologic side effects of cancer therapies, such as chemotherapy and immunotherapy, are increasingly complex, emphasizing the importance of preventive and management strategies to reduce skin toxicity and improve treatment adherence.

This study found that a transdermal delivery system using 3% azone and P407 gel may enhance the skin permeation of doxazosin and finasteride for treating benign prostatic hyperplasia.

A young man with an eating disorder had a life-threatening adrenal crisis due to an autoimmune condition, highlighting the need for better education on managing hormone treatments.

This article reviews the dermatological side effects of chemotherapy, their impact on treatment and patient quality of life, and emphasizes collaboration between oncologists and dermatologists for effective management.

This study found that co-administering glucocorticoids with 5α-reductase inhibitors exacerbated the adverse metabolic effects of glucocorticoids in healthy men.

This review discusses the efficacy and safety of exemestane as a treatment for estrogen-receptor-positive breast cancer and reports no new clinical results.

This review summarizes evidence and adverse event management recommendations for Sacituzumab Govitecan in metastatic triple-negative breast cancer and hormone receptor-positive breast cancer, emphasizing favorable survival data from clinical trials.

This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.

In this study, researchers at Nottingham Children's Renal Unit found that most pediatric patients switching from Prograf to the generic tacrolimus preparation Adoport maintained stable tacrolimus levels and therapeutic effectiveness, supporting Adoport's use as a cost-saving alternative for the NHS.

In this study, bicalutamide showed promise in managing female pattern hair loss and reducing minoxidil-induced hypertrichosis, though further research is necessary to refine its use and establish its role in treatment.

In this conference session, experts reviewed clinical evidence and strategies for using JAK inhibitors in managing alopecia areata, emphasizing optimal treatment practices and individual patient considerations to enhance safety and effectiveness in real-world settings.

This commentary highlights that cetirizine, a widely-used antihistamine, remains effective for various emerging allergic conditions, and new formulations and combination therapies may enhance its effectiveness while being generally well-tolerated.

This study found that while iron supplements are generally well tolerated by patients with anemia, their clinical benefit in those without iron deficiency is modest.

This observational study suggests that antiretroviral drugs that interact with CYP 3A4 enzymes may alter finasteride's effectiveness for hair loss in men treated for HIV.

In this study, researchers found that azathioprine significantly improved hair regrowth in patients with moderate to severe alopecia areata over 10 years, with hair loss decreasing from 74.2% to 5.2% and demonstrating long-term safety and efficacy.

This review highlighted that targeted cancer therapies, while generally causing mild toxicities that can be managed, also pose risks of rare but serious side effects like pneumonitis and cardiotoxicities, emphasizing the need for vigilant monitoring and management to ensure patient safety.

This study found that methotrexate, when administered according to current recommendations, effectively manages rheumatoid arthritis for many patients in Poland, although regular monitoring is necessary due to possible adverse effects.

This research reported that docetaxel is generally safe and effective for elderly patients with solid tumor malignancies, showing no significant age-related differences in efficacy or toxicity.

This study presents case reports of four patients with alopecia areata or alopecia universalis, highlighting varied responses to treatments like prednisone, intralesional triamcinolone, and squaric acid dibutyl ester.

This review examined the common side effects of FGFR inhibitors like erdafitinib, pemigatinib, and futibatinib, and detailed strategies for managing them, highlighting that proactive monitoring and appropriate interventions can effectively mitigate these toxicities.

This case study reports that a combination of PUVA therapy and oral methyl prednisolone initially improved symptoms of a woman's cutaneous T-cell lymphoma but required ongoing treatment due to recurrence.

In this retrospective study, researchers observed that additional rounds of intravenous corticosteroid pulse therapy led to only partial hair regrowth in some rapidly progressive alopecia areata cases, with all participants experiencing relapse, indicating limited efficacy for severe cases resistant to initial treatment.

This article discusses the factors influencing anticancer therapeutic regimens and reviews mechanisms of action and side effects of major chemotherapeutic agents without reporting new research findings.

Quarantine stress likely worsened hair loss in women, but video consultations helped manage their condition and reduce anxiety.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

This chapter reviews the skin side effects associated with targeted cancer therapies and emphasizes the importance of collaboration between oncologists and dermatologists without reporting new results.

Transplant patients often get skin problems, with treatments varying by condition.

In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.